CTLA4 and neoplasm: Similarly, a synergistic effect of the triple combination of vorinostat (HDACI) with anti-CTLA-4 and anti-PD-1 was observed in a triple-negative 4T1 breast cancer mouse model through boosting the anti-tumor activity [177].